Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.

The clinical course of B-cell chronic lymphocytic leukemia (B-CLL) is variable, and novel biologic parameters need to be added to the clinical staging systems to predict an indolent or aggressive outcome. We investigated the 70-kDa zeta-associated protein (ZAP-70), CD38, soluble CD23 (sCD23), and cytogenetics in 289 patients with B-CLL. Both a shorter progression-free survival (PFS) and overall survival (OS) were observed in ZAP-70(+) (P < .001), in CD38(+) (P < .001) and in sCD23(+) patients (P < .001 and P = .013, respectively). ZAP-70(+)CD38(+) or ZAP-70(+) patients with an unmutated IgV(H) status showed both a shorter PFS (P < .001) and OS (P < .001 and P < .001, respectively) as compared with ZAP-70(-)/CD38(-) or ZAP-70(-) patients with mutated IgV(H) genes. Discordant patients showed an intermediate outcome. Note, ZAP-70(+) patients even if CD38(-) or mutated showed a shorter PFS, whereas ZAP-70(-) patients even if CD38(+) or unmutated had a longer PFS. Furthermore, ZAP-70 positivity was associated with a shorter PFS both within normal karyotype (P < .001) and within the poor-risk cytogenetic subset (P = .02). The predictive value of ZAP-70 expression was confirmed in multivariate analysis. Thus, ZAP-70 protein determined by flow cytometry improves the prognostic significance of cytogenetics and appears to be a better predictor of outcomes than IgV(H) gene mutational status. On this line, we recommend and are also interested in conducting a prospective randomized trial of early intervention versus observation for ZAP-70(+) patients.

[1]  S. Johnson,et al.  Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. , 2005, Clinical and laboratory haematology.

[2]  P. Sonego,et al.  Mutational status of IgVH genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection? , 2005, Leukemia.

[3]  L. Klein-Hitpass,et al.  Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia , 2005, Leukemia.

[4]  L. Rassenti,et al.  ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. , 2005, Blood.

[5]  A. Wiestner.  More ZAP for chronic lymphocytic leukemia (CLL). , 2005, Blood.

[6]  E. Montserrat,et al.  Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. , 2005, Haematologica.

[7]  A. Venditti,et al.  ZAP-70 Protein Retains Its Prognostic Significance within Interphase Cytogenetic Groups in B-Cell Chronic Lymphocytic Leukemia (B-CLL). , 2004 .

[8]  T. Hamblin.  Predicting Progression--ZAP-70 in CLL. , 2004, The New England journal of medicine.

[9]  Arthur Weiss,et al.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.

[10]  C. Pucillo,et al.  Analysis of IgVH gene mutations in B cell chronic lymphocytic leukaemia according to antigen‐driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery , 2004, British journal of haematology.

[11]  Adrian Wiestner,et al.  ZAP-70 expression and prognosis in chronic lymphocytic leukaemia , 2004, The Lancet.

[12]  T. Möröy,et al.  ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia , 2003, Leukemia.

[13]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[14]  Arthur Weiss,et al.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. , 2002, Blood.

[15]  Xiao-Jie Yan,et al.  Chronic Lymphocytic Leukemia B Cells Can Undergo Somatic Hypermutation and Intraclonal Immunoglobulin VHDJH Gene Diversification , 2002, The Journal of experimental medicine.

[16]  Xiao-Jie Yan,et al.  B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. , 2002, Blood.

[17]  D. Oscier,et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.

[18]  L. Bullinger,et al.  Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course , 2002, Leukemia.

[19]  David Botstein,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[20]  G. Capelli,et al.  Clinical significance of CD38 expression in chronic lymphocytic leukemia. , 2001, Blood.

[21]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[22]  B. Cheson,et al.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[23]  A. Pinto,et al.  Normalizing complementary DNA by quantitative reverse transcriptase-polymerase chain reaction of beta2-microglobulin: molecular monitoring of minimal residual disease in acute promyelocytic leukemia. , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[24]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[25]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[26]  T J Hamblin,et al.  B-cell chronic lymphocytic leukemia: a bird of a different feather. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Rassenti,et al.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.

[28]  E J Freireich,et al.  Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. , 1998, Blood.

[29]  D. Serraino,et al.  CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. , 1997, Blood.

[30]  S. Chevret,et al.  Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. , 1996, Blood.

[31]  S. Zupo,et al.  CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. , 1996, Blood.

[32]  K. Rajewsky.  Clonal selection and learning in the antibody system , 1996, Nature.

[33]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[34]  R. Aebersold,et al.  ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: the tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity , 1995, The Journal of experimental medicine.

[35]  D. Catovsky,et al.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. , 1994, Leukemia.

[36]  Arthur Weiss,et al.  ZAP-70: A 70 kd protein-tyrosine kinase that associates with the TCR ζ chain , 1992, Cell.

[37]  C W Turck,et al.  ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. , 1992, Cell.

[38]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.